SEC filer · CIK 0001001233 · SGMOQ
Sangamo Therapeutics, Inc.
Sangamo Therapeutics revenue: $39.6 million for the year ending 2025-12-31. Net income: -$122.9 million.
Latest annual reportReceipt
10-K for the fiscal year ended , filed
- Revenue
- $39.6 million
- Net income
- -$122.9 million
- Diluted EPS
- -$0.44 per share
- Operating cash flow
- -$97.2 million
- Cash
- $20.9 million
- Total assets
- $59.7 million
- Total liabilities
- $74.0 million
As filed
Open the 10-K on SEC.govContext from the filing
For Sangamo Therapeutics in 2021 and 2022, diluted loss per share excludes anti-dilutive options, restricted stock units and employee purchase-plan shares. The 2021 numerator is loss attributable to Sangamo stockholders ($178.286 million), after excluding $11,000 of non-controlling-interest loss. The statement displays weighted-average shares in thousands; inline scale 3 supports the full share counts. Reported USD EPS and historical periods are retained. Read the source filing.
For Sangamo Therapeutics in 2024 and 2025, the filing excludes 50.5 million and 96.5 million potential shares, respectively, because their inclusion would be anti-dilutive during losses. Basic and diluted loss per share therefore use the same weighted-average shares. The statement displays share counts in thousands and inline tags use scale 3; full share counts and reported USD EPS are retained. Read the source filing.
Every reported measure
The latest value of each measure the company reports, as filed. Choose one for its full history, its definition and the filing behind each figure. Separate currencies and reporting intervals stay separate rows; these are reported amounts, not prices.
| Measure | Period start | Period end | Value | Filed |
|---|---|---|---|---|
| Total assets | - | 2025-12-31 | $59.7 million | 2026-03-30 |
| Total liabilities | - | 2025-12-31 | $74.0 million | 2026-03-30 |
| Stockholders equity | - | 2025-12-31 | -$14.3 million | 2026-03-30 |
| Cash and cash equivalents | - | 2025-12-31 | $20.9 million | 2026-03-30 |
| Net income or loss | 2025-01-01 | 2025-12-31 | -$122.9 million | 2026-03-30 |
| Operating cash flow | 2025-01-01 | 2025-12-31 | -$97.2 million | 2026-03-30 |
| Capital expenditure payments | 2025-01-01 | 2025-12-31 | $102.0 thousand | 2026-03-30 |
| Contract revenue excluding tax | 2025-01-01 | 2025-12-31 | $39.6 million | 2026-03-30 |
| Financing cash flow | 2025-01-01 | 2025-12-31 | $70.7 million | 2026-03-30 |
| Investing cash flow | 2025-01-01 | 2025-12-31 | -$102.0 thousand | 2026-03-30 |
| Retained earnings or deficit | - | 2025-12-31 | -$1.63 billion | 2026-03-30 |
| Basic weighted-average shares | 2025-01-01 | 2025-12-31 | 280.2 million shares | 2026-03-30 |
| Diluted weighted-average shares | 2025-01-01 | 2025-12-31 | 280.2 million shares | 2026-03-30 |
| Basic earnings per share | 2025-01-01 | 2025-12-31 | -$0.44 per share | 2026-03-30 |
| Diluted earnings per share | 2025-01-01 | 2025-12-31 | -$0.44 per share | 2026-03-30 |
| Income tax expense or benefit | 2025-01-01 | 2025-12-31 | -$568.0 thousand | 2026-03-30 |
| Net property, plant and equipment | - | 2025-12-31 | $11.0 million | 2026-03-30 |
| Share-based compensation expense | 2025-01-01 | 2025-12-31 | $9.08 million | 2026-03-30 |
| Operating income or loss | 2025-01-01 | 2025-12-31 | -$121.2 million | 2026-03-30 |
| Current assets | - | 2025-12-31 | $35.8 million | 2026-03-30 |
| Current liabilities | - | 2025-12-31 | $42.5 million | 2026-03-30 |
| Current accounts payable | - | 2025-12-31 | $14.4 million | 2026-03-30 |
| Goodwill carrying amount | - | 2024-12-31 | $0 | 2025-03-17 |
| Net current accounts receivable | - | 2025-12-31 | $371.0 thousand | 2026-03-30 |
| Operating expenses | 2025-01-01 | 2025-12-31 | $160.8 million | 2026-03-30 |
| Research and development expense | 2025-01-01 | 2025-12-31 | $112.7 million | 2026-03-30 |
| Common shares outstanding | - | 2025-12-31 | 350.7 million shares | 2026-03-30 |
| Cash including restricted cash | - | 2025-12-31 | $20.9 million | 2026-03-30 |
| Accumulated other comprehensive income or loss | - | 2025-12-31 | -$1.46 million | 2026-03-30 |
| Operating lease right-of-use asset | - | 2025-12-31 | $3.06 million | 2026-03-30 |
| Operating lease liability | - | 2025-12-31 | $26.8 million | 2026-03-30 |
| Gross property, plant and equipment | - | 2025-12-31 | $53.3 million | 2026-03-30 |
| Accumulated depreciation on property, plant and equipment | - | 2025-12-31 | $42.2 million | 2026-03-30 |
| Net intangible assets excluding goodwill | - | 2024-12-31 | $0 | 2025-03-17 |
| Other noncurrent assets | - | 2025-12-31 | $871.0 thousand | 2026-03-30 |
| Other noncurrent liabilities | - | 2025-12-31 | $580.0 thousand | 2026-03-30 |
| Accrued current liabilities | - | 2025-12-31 | $9.41 million | 2026-03-30 |
| Prepaid expenses and other current assets | - | 2025-12-31 | $4.37 million | 2026-03-30 |
| Current contract liabilities | - | 2025-12-31 | $899.0 thousand | 2026-03-30 |
| Net deferred tax assets | - | 2025-12-31 | $770.0 thousand | 2026-03-30 |
| Pre-tax income or loss from continuing operations | 2025-01-01 | 2025-12-31 | -$123.5 million | 2026-03-30 |
| Comprehensive income or loss | 2025-01-01 | 2025-12-31 | -$116.9 million | 2026-03-30 |
| General and administrative expense | 2025-01-01 | 2025-12-31 | $34.9 million | 2026-03-30 |
| Depreciation, depletion and amortization | 2025-01-01 | 2025-12-31 | $3.96 million | 2026-03-30 |
| Other nonoperating income or expense | 2025-01-01 | 2025-12-31 | -$3.56 million | 2026-03-30 |
| Deferred income tax expense or benefit | 2024-01-01 | 2024-12-31 | $0 | 2025-03-17 |
| Proceeds from issuing common stock | 2025-01-01 | 2025-12-31 | $21.5 million | 2026-03-30 |
| Operating lease payments | 2025-01-01 | 2025-12-31 | $6.40 million | 2026-03-30 |
| Change in accounts receivable | 2025-01-01 | 2025-12-31 | -$155.0 thousand | 2026-03-30 |
Older measures: 6 not reported in the two years before 2026-09-20
| Measure | Period start | Period end | Value | Filed |
|---|---|---|---|---|
| Revenue | 2017-01-01 | 2017-12-31 | $36.6 million | 2018-03-01 |
| Additional paid-in capital | - | 2013-12-31 | $423.2 million | 2014-02-24 |
| Total equity including noncontrolling interests | - | 2023-12-31 | $82.9 million | 2024-03-13 |
| Net deferred tax liabilities | - | 2023-12-31 | $0 | 2024-03-13 |
| Profit or loss including noncontrolling interests | 2023-01-01 | 2023-12-31 | -$257.8 million | 2024-03-13 |
| Nonoperating income or expense | 2014-01-01 | 2014-12-31 | $364.0 thousand | 2015-02-25 |
Filings
- 10-Q filed 2026-05-14
- 10-K filed 2026-03-30
- 10-Q filed 2025-11-06
- 10-Q filed 2025-08-07
- 10-Q filed 2025-05-12
60 Sangamo Therapeutics filings with published measures: what each annual or quarterly report tagged, with the periods it covered, as reported in that filing. The histories above show the latest-filed value per period.
Inspect the source
- Entity
- SANGAMO THERAPEUTICS, INC. / CIK 0001001233
- Captured
- SEC response SHA-256
f678a4cd3364c095e387026eb9f115ac294a4697b3c5aebe6c86663002f694af
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
The MCP server is free and MIT-licensed: npx -y canli-mcp. If these records help your research, a star on GitHub helps other researchers find them.
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001001233.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))